Location: Stage

 Chair’s Opening Remarks & Setting the Scene

• A look at the day ahead – what will be the key takeaways we should achieve by the end of this summit?
• How far have we come in the CD47|SIRPα space since last April?

Kipp Weiskopf, Whitehead Fellow, Whitehead Institute

Keynote Presentation: Fundamental Biology of the CD47|SIRPα Checkpoint

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research, Amsterdam University Medical Center

Presentation: A Novel MOA-reflective Bioassay for Quantifying Potency of Therapeutics Targeting the SIRPα|CD47 Signaling Axis

• Assay principle and relevance to MOA of SIRPα/CD47 signaling in macrophages
• Assay characterization and optimization/development history
• Suitability of the assay for potency determination and characterization of anti-SIRPα/anti-CD47
• Therapeutics

Jane Lamerdin, Director, R&D, Eurofins DiscoverX

Wellness Break

Get-up and have a stretch before the next session begins.

Panel Discussion: What Impact is our Current Level of Understanding of the CD47|SIRPα Checkpoint Having on the Industry?

• What knowledge do we need to further the development of CD47|SIRP​α​ targeted therapies? 
• What are the specific hurdles within research that prevents information about the CD47|SIRP​α​ being discovered?
• Do we understand sufficiently which immune functions are controlled by CD47-SIRPα and how?
• As we move further into human trials, what are we expecting to learn about the fundamental biology of CD47/SIRPa?

Dan Pereira, CSO, Arch Oncology

Michal Caspi Tal, Instructor & Team Lead, Stanford University

Anthony Schwartz,CEO, Morphiex

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research, Amsterdam University Medical Center

Location: Networking

Speed Networking

In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-up’s throughout the rest of the event. 

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

Location: Stage

Presentation: What Do We Know About the Fundamental Biology Behind Alternative SIRP Homologs and an Overview of OSE Immunotherapeutics’ Approach

Nicolas Poirier, CSO, OSE Immunotherapeutics

Presentation: How Do Macrophages Work In Relation To CD47|SIRPα?

• We learn more about the fundamental biology behind macrophages and how they interact with CD47.  
• Why Macrophages rather than dendritic/myeloid cells? 
• What is the role of macrophage polarity as it pertains to promoting phagocytosis following SIRPa/CD47 blockade?

Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute

Wellness Break

Get-up and have a stretch before the next session begins.

Panel Discussion: What Does “Eat Me” Mechanistically Mean for Macrophages In Relation To CD47|SIRPα?

• How do we activate and how do we increase macrophage activity? 
• What are the different types of macrophages, does the targeted therapy approach need to change depending on the type of macrophage?
• Can CD47/SIRPa blockade single-handedly influence what macrophages do with the tumor antigens after they are ‘eaten’?
• What other signals/pathways in macrophages need to be engaged?
• How do we measure/confirm macrophage phagocytosis in a clinical trial setting? 

Siddhartha Mitra, Assistant Professor, University of Colorado

Sergio Trombetta, Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim

Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute

Takashi Matozaki, Professor, Dean of the Graduate School of Medicine, Kobe University

The CD47/SIRPα Summit includes an extended break in the middle to give you ample time for lunch and another chance to catch-up on the day job. Or if you have time, you can use this break for 1-2-1 meetings or open networking.

Location: Stage

Presentation: QPCTL – A Druggable Modifier of the CD47/SIRP Therapeutic Axis 

Sebastian Nijman, Founder & Managing Director, Scenic Biotech

Presentation: Tackling Solid Cancers using a Bispecific Antibody Approach – Light Chain Bioscience

• A look at the advantages of targeting CD47 with a bispecific antibody approach. 
• We hear about Mesothelin as a target for solid cancers. 
• An insight into preclinical data for the CD47 x Mesothelin bispecific antibody. 

 Limin Shang, Pharmacology Director, LightChain Bioscience

Wellness Break

Get-up and have a stretch before the next session begins.

Panel Discussion: Chemotherapy, T-cell Immunotherapy and Radiotherapy – Where do these Fit in Combination with CD47|SIRPα?  

• What do we know so far about combining these targets with CD47|SIRPα both preclinically and clinically?
• How effectively does radiotherapy work alongside CD47|SIRPα? 
• What are the risks of combining these immuno-oncology targets?
• What are the potential impacts of immunogenic vs non-immunogenic cell killing on CD47|Sirpa compounds, does one route work better than the other? 
• How predictive/how useful are preclinical models in this space?

Siddhartha Mitra, Assistant Professor, University of Colorado

André Veillette, Professor, Department of Medicine, University of Montreal

Timothy Zheng, Executive Director, Immune Modulation, Boehringer Ingelheim

Location: Stage

Presentation: ALX148: Designed For Safety To Maximize Efficacy

• Design of ALX148 and mechanistic insights into its safety/efficacy profile
• Overview of clinical results from the ALX148 program

Jaume Pons, President & CEO, ALX Oncology

Presentation: TJC4 – A Differentiated CD47 Antibody in Clinical Development

• An insight into how I-Mab Biopharma discovered an antibody with differentiated properties to reduce RBC binding. 
• We learn about I-Mab Biopharma’s attempt to understand the mechanisms underlying these differentiated properties. 

Claire Xu, Head of US Site, I-Mab Biopharma

Wellness Break

Get-up and have a stretch before the next session begins.

Panel Discussion: What are the Predictive Biomarkers Arising when Targeting CD47|SIRPα Pathways?

• What are the best biomarker strategies to validate how clinical trials are going?
• SIRPα/CD47 tumoral expression: is there any correlation with clinical efficacy?
• Macrophage/T-cell infiltrates: is there any correlation with clinical efficacy?
• What other biomarkers should be considered in regards to CD47|SIRPα drugs? 
• What biomarkers are biotech companies using to track macrophages in clinic?

Moderated by: Nicolas Poirier, CSO, OSE Immunotherapeutics

Claire Xu, Head of US Site, I-Mab Biopharma

André Veillette, Professor, Department of Medicine, University of Montreal

Spencer Liang, Senior Director, Head of Immuno-Oncology, Alector 

Limin Shang, Pharmacology Director, LightChain Bioscience

Location: Stage

 Chair’s Opening Remarks & Setting the Scene

• What have we learned so far at CD47|SIRPα 2020? 
• What can we expect from today? 

Siddhartha Mitra, Assistant Professor, University of Colorado

Presentation: An Insight into Trillium Therapeutics’ Progress and What’s To Come.  

Yaping Shou, Chief Medical Officer, Trillium Therapeutics

Presentation: Genetic Variations in SIRPα Impact CD47 Interactions.

Michal Caspi Tal, Instructor & Team Lead, Stanford University

Wellness Break

Get-up and have a stretch before the next session begins.

Panel Discussion: How Can We Manage Toxicity and Improve Clinical Practice?

• What toxicities have been identified during preclinical & clinical trials? 
• Are there specific causes for toxicity and how can we negate these? 
• Are pre-clinical non-human samples posing problems for future clinical trials? 
• The RACE For Children Act comes into effect in August 2020, how will this affect clinical trials?
• How else can we build best practices in clinic? 

Tabitha Cooney, Physician,  Neuro-Oncology, Dana Farber Cancer Institute 

Michael Dougan,Assistant Professor, Medicine, Harvard Medical School

Daniel Masylar, VP of Clinical Development for Oncology, Alector

Location: Stage

Presentation: CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity.

Taylor Schreiber, CEO, Shattuck Labs

Presentation: AO-176, A Highly Differentiated Clinical Stage Anti-CD47 Antibody.

• We learn how Arch Oncology is working to bridge innate and adaptive anti-tumor immunity through development of AO-176.
• An insight into the clinical trials for AO-176 and what’s to come.

Dan Pereira, CSO, Arch Oncology 

Wellness Break

Get-up and have a stretch before the next session begins.

Presentation: An Insight Into Alector’s Novel Approach to Drive Anti-Tumor Immunity. 

Andrew Picentic, Staff Scientist & Program Lead, Alector

Panel Discussion: Reflection and Progression – Where are We and What’s Next for CD47|SIRPα?

• What challenges have we faced and how can we overcome these?
• Where do we expect to see the most growth in the next year? 
• Should enhancing mediated-macrophage phagocytosis be a focus going forward? 
• How is the future work on emerging “don’t eat me” signals going to benefit from our work with CD47/SIRPα?
• What have been our biggest takeaways from the CD47/SIRPα 2020 Summit

Timothy Zheng, Executive Director, Immune Modulation, Boehringer Ingelheim

Taylor Schreiber, CEO, Shattuck Labs

Sebastian Nijman, Founder & Managing Director, Scenic Biotech

Location: Sessions

Open Q&A with Speakers

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

Timothy Zheng, Executive Director, Immune Modulation, Boehringer Ingelheim

Taylor Schreiber, CEO, Shattuck Labs

Sebastian Nijman, Founder & Managing Director, Scenic Biotech

Close of The CD47/SIRPa Summit

Roll straight into the rest of your Thursday with no flight to catch!